RESEARCH TRIANGLE PARK, N.C.,
Oct. 22, 2016 /PRNewswire/
-- Liquidia Technologies, Inc. today announced that the
Company will present at the 6th Annual Partnership Opportunities in
Drug Development (PODD) conference being held October 27–28, 2016
in Boston, MA. PODD is a strategic
level program for pharma and biotech business development
professionals that provides an overview of the latest developments
in drug delivery technologies and opportunities to improve
therapies.
Dr. Kevin Herlihy, Principal
Scientist at Liquidia Technologies, will give a presentation titled
Engineering Uniform Particles to Improve Drug Performance in
which he will introduce the PRINT® technology for precisely
engineering uniform drug particles to improve the performance of
therapeutic medicines. He will highlight specific advantages to the
controlled-release of small molecules and proteins.
Using its proprietary PRINT technology, Liquidia can
optimize the performance of existing and novel therapeutics
regardless of their size, route of administration or therapeutic
indication. PRINT-optimized product candidates are in, or will soon
enter, clinical development in pulmonary disease, post-operative
pain management, and ophthalmology. In addition to advancing
product candidates from its own pipeline, Liquidia actively
partners with world-class collaborators, such as GlaxoSmithKline,
to expand the applications for PRINT.
ABOUT LIQUIDIA TECHNOLOGIES
Liquidia Technologies is a biopharmaceutical company that has
pioneered a simple, elegant solution to improve the performance of
medicines by precisely engineering drug particles. Through its
proprietary PRINT® technology, Liquidia has become the only company
in the world that can improve the efficacy, safety, or route of
administration, of nearly any therapeutic molecule by designing
drug particles in a virtually unlimited number of compositions,
sizes, or shapes. Leveraging aspects of biology and
pharmaceutical chemistry with polymer science, PRINT technology
represents an entirely novel approach to drug development and
production, yet one that is also GMP capable, fully-scalable, and
highly cost-effective. PRINT-optimized product candidates are
in – or will soon enter – clinical development in pulmonary
diseases, post-operative pain management and ophthalmology. In
addition to advancing product candidates from its own pipeline,
Liquidia actively partners with world-class collaborators,
including GlaxoSmithKline, to expand the applications for PRINT
technology.
Logo - http://photos.prnewswire.com/prnh/20161022/431526LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/liquidia-technologies-to-present-at-6th-annual-partnership-opportunities-in-drug-development-podd-conference-300349503.html
SOURCE Liquidia Technologies